Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment.

Casabianca, A

Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. [electronic resource] - Infection Aug 2011 - 375-8 p. digital

Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

1439-0973

10.1007/s15010-011-0109-5 doi


Aged
Amphotericin B--therapeutic use
Antibodies, Monoclonal, Murine-Derived--therapeutic use
Antineoplastic Agents--therapeutic use
Antiprotozoal Agents--therapeutic use
Bone Marrow--parasitology
Fatal Outcome
Female
Humans
Immunocompromised Host
Italy
Leishmania infantum--drug effects
Leishmaniasis, Visceral--blood
Leukocytes, Mononuclear--parasitology
Lymphoma, Non-Hodgkin--drug therapy
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Recurrence
Rituximab